iTeos Therapeutics - Immunotherapies By Design
Cancer Immunotherapies by Design ™
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients . We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.
introduction
Pipeline
iTeos focuses upon selected key mechanisms by which cancer cells suppress the immune system.
The identification of these mechanisms is based on gene expression profiles of immune cell subsets as they recognize tumor cell targets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of laboratory models.
| Program | Trial Design | Indications | Preclinical | Phase 1 | Phase 1b/2a | Key upcoming milestones |
|---|---|---|---|---|---|---|
| A2A Receptor Antagonist | ||||||
|
Inupadenant (EOS-850)
|
Monotherapy | Solid tumors | Initial expansion results 1H 2021 | |||
| + pembrolizumab | PD-1-Resistant Melanoma | Initiated 3Q 2020 | ||||
| + pembrolizumab | Castrate-R Prostate Cancer | Initiated 3Q 2020 | ||||
| + Pac-Carbo | TNBC | Initiated 3Q 2020 | ||||
| Anti-TIGIT mAb ADCC-enabled | ||||||
|
EOS-448
|
Dose Finding, PK/PD | Solid tumors | Presentation of initial results 1H 2021 | |||
| Mono / + Combo | Multiple Myeloma | Initiation mid-2021 | ||||
| + PD-(L)1 | NSCLC | Initiation mid-2021 | ||||
| Inupadenant +/- Chemo | Solid Tumors | Initiation mid-2021 | ||||
| Preclinical pipeline | ||||||
|
Adenosine Pathway Inhibitor
|
Oncology | Candidate selection in 2021 | ||||